New‐generation BH3‐mimetics, such as venetoclax (ABT‐199), offer high selectivity for BCL‐2 and substantially reduce the risk of thrombocytopenia compared to earlier multitarget agents like navitoclax, which also inhibits BCL‐XL and destabilizes platelet survival [15, 16]. This evidence concerns the gene BCL2 and Thrombocytopenia.